Overview
Longeveron is a clinical-stage regenerative medicine biotechnology company headquartered in Miami, Florida, developing culture-expanded mesenchymal stem cell therapies to address life-threatening and chronic aging-related conditions. The company's lead investigational product, laromestrocel (Lomecel-B™), is derived from bone marrow-sourced mesenchymal stem cells from young healthy adult donors and is designed to modulate immune function and promote tissue repair. Longeveron is advancing multiple clinical programs targeting hypoplastic left heart syndrome, Alzheimer's disease, aging-related frailty, and other age-associated pathologies, with the goal of improving healthspan and extending longevity through cellular regeneration.